Current developments in LC-MS for pharmaceutical analysis.
about
A nano LC-MALDI mass spectrometry droplet interface for the analysis of complex protein samplesAn overview of some recent developments in ionization methods for mass spectrometry.A high-throughput liquid chromatography tandem mass spectrometry method for the comparative determination of fluticasone propionate by reversed-phase liquid chromatography and capillary electrophoresis methods in pharmaceutical nasal sprays.Determination of cortisol production rates with contemporary liquid chromatography-mass spectrometry to measure cortisol-d(3) dilution after infusion of deuterated tracer.The need for better data about counterfeit drugs in developing countries: a proposed standard research methodology tested in Chennai, India.Recent application of analytical methods to phase I and phase II drugs development: a review.Development and validation of a sensitive and high-throughput LC-MS/MS method for the simultaneous determination of esomeprazole and naproxen in human plasma.Safety and efficacy: the role of chemistry, manufacturing, and controls in pharmaceutical drug development.NanoHPLC-nanoESI(+)-MS/MS quantitation of bis-N7-guanine DNA-DNA cross-links in tissues of B6C3F1 mice exposed to subppm levels of 1,3-butadiene.Liquid chromatography-electrospray ionization-mass spectrometry: the future of DNA adduct detection.Current technologies and considerations for drug bioanalysis in oral fluid.Separation methods for captopril in pharmaceuticals and biological fluids.Nano-liquid chromatography in pharmaceutical and biomedical research.Emerging liquid chromatography-mass spectrometry technologies improving dried blood spot analysis.Size does matter! Label-free detection of small molecule-protein interaction.Potential of monitoring isotopologues by quantitative gas chromatography with time-of-flight mass spectrometry for metabolomic assay.High-throughput quantitative and qualitative analysis of microsomal incubations by cocktail analysis with an ultraperformance liquid chromatography-quadrupole time-of-flight mass spectrometer system.Determination of fesoterodine in pharmaceutical formulations by using liquid chromatography-tandem mass spectrometry.Quantitation of a de-fluorinated analogue of casopitant mesylate by normal-phase liquid chromatography/mass spectrometry.Bioactivity-guided fractionation and analysis of compounds with anti-influenza virus activity from Gardenia jasminoides Ellis.Discovery pharmacokinetic studies in mice using serial microsampling, dried blood spots and microbore LC-MS/MS.The European clinical trials directive-a regulatory approach for filing drug substance information.Application of HPLC and ESI-MS techniques in the analysis of phenolic acids and flavonoids from green leafy vegetables (GLVs).Bioanalytical methods for the detection of antidiabetic drugs: a review.Highly Sensitive LC-MS-MS Method for the Determination of Tacrine in Rat Plasma: Application to Pharmacokinetic Studies in Rats.Stressed Kinetics and Pharmacokinetics of Curcumin Nanoemulsion Using Validated Ultrahigh-Performance Liquid Chromatography–Synapt Mass Spectrometry (UPLC–MS/MS–ESI-Q-TOF)
P2860
Q27321232-B8282437-7DD7-4FA8-93B0-7D3E7BCBA7E6Q33202059-AAB4A1DC-6705-46E0-A714-D6E029789F9FQ33444404-E1FA2BF3-F9B0-4438-A36E-DC8EB2159A88Q33449027-F0AF5646-565B-4B8B-934C-498AFFD9F775Q33950863-93681E7B-5C24-4136-A8B7-66B49674B2FEQ33997398-C75C3146-1F62-4A6F-BAC8-BE5BEF6C0DC3Q34618109-D9FCED7F-7CBA-4D4E-BF31-3F39B0AB973AQ35756163-C3BF1D3B-3643-44F4-A01D-A9C42B4BC219Q35819432-6FBD1195-4555-49B8-95B4-325F2515B87DQ36307099-4D0C8E9F-9BF5-4731-9BAD-DA33982E4196Q37810195-C1BBFE3A-B8B6-48D6-B4C1-318CB2EB4FCAQ38021709-34D92726-F7C5-4F4B-BFE5-E08A62AE7C80Q38098981-A3C471FF-0B9E-4293-9B8F-678319D3DCA8Q38201783-6715B3C7-DA7D-4635-9316-45BF49D68CD7Q38210964-37286413-1A25-4319-B9AF-C290E439E7DFQ40111593-3E30D5ED-BD9F-4973-8A85-D9A6C3D22653Q41679401-1D3A50A1-12C8-472D-B6A3-FA8B80159A64Q42775053-72A89639-9302-4CEA-8AF6-5892B0408E70Q42925412-BAB26DE7-C3F5-456C-B706-BCB6D70C53F9Q45359965-9D3C0522-4829-4F78-BE60-005ADF8DF4D9Q47735810-BB47258D-479F-48A7-9F35-58619D5404D0Q48603349-A155F715-826F-44AD-9D73-300D7847CF69Q49187603-02F66F3A-A007-4463-8798-5455A4C1B2FEQ49679474-2556E47D-0C7F-4674-8D04-0C3339DF9568Q53286758-0392D683-7D5A-4D7C-A2D2-CFBAC78F639CQ57348957-24E628E8-42F2-471B-A802-4B2DEE203DDD
P2860
Current developments in LC-MS for pharmaceutical analysis.
description
2002 nî lūn-bûn
@nan
2002 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Current developments in LC-MS for pharmaceutical analysis.
@ast
Current developments in LC-MS for pharmaceutical analysis.
@en
type
label
Current developments in LC-MS for pharmaceutical analysis.
@ast
Current developments in LC-MS for pharmaceutical analysis.
@en
prefLabel
Current developments in LC-MS for pharmaceutical analysis.
@ast
Current developments in LC-MS for pharmaceutical analysis.
@en
P356
P1476
Current developments in LC-MS for pharmaceutical analysis.
@en
P2093
Chang-Kee Lim
P304
P356
10.1248/BPB.25.547
P577
2002-05-01T00:00:00Z